Form 8-K Dogwood Therapeutics, For: Jan 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Dogwood Therapeutics provides 2025 progress update
January 20, 2026 8:38 AM ESTDogwood Therapeutics Inc. (NASDAQ: DWTX) issued a corporate update detailing progress in its development of non-opioid medicines for pain and neuropathy treatment.
The biotechnology company reported recruiting over 100 patients for its Halneuron Phase 2b Chemotherapy Induced Pain study, completing an interim analysis to determine final study sample size and analysis... More



